Latest News and Press Releases

CHARLOTTE, N.C., June 19, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the publication in Neurology of its pivotal, Phase 3 study 301, a multicenter,...

-First Presentation of Integrated Data Analyses From Two Pivotal Trials -Data Shows Statistically Significant Improvement in Symptoms of NOH vs. Placebo CHARLOTTE, N.C. and STOCKHOLM, Sweden,...

CHARLOTTE, N.C., June 6, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust...

CHARLOTTE, N.C., May 8, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Chelsea) (Nasdaq:CHTP), a biopharmaceutical development company, has entered into a definitive agreement to...

By acquiring Chelsea Therapeutics, Lundbeck gains the rights to Chelsea Therapeutics' recently FDA-approved product, NORTHERATM (droxidopa), which is expected to be launched later in 2014...

CHARLOTTE, N.C., March 11, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year ended December 31,...

CHARLOTTE, N.C., Feb. 28, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), which recently received Food and Drug Administration (FDA) accelerated approval of NORTHERATM...

CHARLOTTE, N.C., Feb. 14, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today issued the following statement regarding the U.S. Food and Drug Administration (FDA)...

CHARLOTTE, N.C., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that Keith W. Schmidt has been named Chief Commercial Officer, effective...

CHARLOTTE, N.C., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that Joseph G. Oliveto has been named President and Chief Executive Officer...